药物依从性促进系统减少晚期肾移植排斥:质量改进研究
该质量改进研究在辛辛那提儿童医院肾移植受者中实施MAPS(药物依从性促进系统),采用中断时间序列分析。结果显示,实施后每月排斥率从每100患者月1.61次降至0.88次,多变量分析中MAPS与排斥发生率降低50%相关(IRR 0.50,95%CI 0.27-0.91,P=0.02)。
要点
- MAPS实施后急性排斥发生率降低50%(IRR 0.50,95%CI 0.27-0.91)。
- 每月排斥率从1.61次/100患者月降至0.88次/100患者月。
- DSA阳性与排斥风险升高相关(IRR 2.27,P=0.02)。
核心结论
- 临床实施基于证据的依从性促进策略与2年内急性排斥发生率降低50%相关。
研究设计与样本
- 中断时间序列研究,纳入2014至2017年在辛辛那提儿童医院接受肾移植≥1年且服用≥1种免疫抑制剂的受者。
主要发现
- 实施前26个月每月排斥率为1.61次/100患者月,实施后22个月降至0.88次/100患者月。
- 多变量分析中MAPS与排斥发生率降低50%相关(IRR 0.50,95%CI 0.27-0.91,P=0.02)。
- DSA与排斥发生率相关(IRR 2.27,P=0.02),移植后时间每增加1年排斥风险降低(IRR 0.87,P=0.02)。
临床怎么用
- 可借鉴MAPS的多组分策略: staff培训、电子病历筛查、障碍评估、专人干预、共享决策、随访评估及可选电子监测。
局限性
- 单中心研究,可能存在未测量变量混杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: Adolescent and young adult kidney transplant recipients have a high risk of rejection related to suboptimal adherence. Multicomponent interventions improve adherence in controlled trials, but clinical implementation is lacking. We describe an initiative to reduce allograft rejection using evidence-based adherence promotion strategies. STUDY DESIGN: Interrupted time series. SETTING & PARTICIPANTS: Kidney transplant recipients cared for at Cincinnati Children's Hospital ≥ 1 year after transplant and taking ≥1 immunosuppressive medication(s) from 2014 through 2017. QUALITY IMPROVEMENT ACTIVITIES: The following interventions, collectively called MAPS (Medication Adherence Promotion System), were implemented over 14 months: (1) adherence promotion training for clinical staff, 2) electronic health record-supported adherence risk screening, (3) systematic assessment of medication adherence barriers, (4) designation of specific staff to address adherence barriers, (5) shared decision-making with the patients to overcome adherence barriers, (6) follow-up evaluation to assess progress, and (7) optional electronic medication monitoring. OUTCOMES: Primary Outcome: Late acute rejection. Process measures were conducted to assess barriers, identify barriers, and perform interventions. The secondary outcomes/balancing measures were de novo donor-specific antibodies (DSA), biopsy rate, and rejections per biopsy. ANALYTICAL APPROACH: Time series analysis using statistical process control evaluated patient-days between acute rejections as well as monthly rejections per 100 patient-months before and after implementation. To control for known rejection risk factors including changes in treatment and case mix, multivariable analyses were performed. RESULTS: The monthly rejection rate fell from 1.61 rejections per 100 patient-months in the 26 months before implementation to 0.88 rejections per 100 patient-months in the 22 months after implementation. In the multivariable analysis, MAPS was associated with a 50% reduction in rejection incidence (incidence rate ratio, 0.50 [95% CI, 0.27-0.91]; P = 0.02). DSA and time since transplant (per each additional year) were also associated with rejection incidence (incidence rate ratio, 2.27 [P = 0.02] and 0.87 [P = 0.02], respectively). LIMITATIONS: Single-center study, and potential confounding by unmeasured variables. CONCLUSIONS: Clinical implementation of evidence-based adherence-promotion strategies was associated with a 50% reduction in acute rejection incidence over 2 years.
引用
- Hooper DK, Varnell CD, Rich K, et al. A Medication Adherence Promotion System to Reduce Late Kidney Allograft Rejection: A Quality Improvement Study. Am J Kidney Dis. 2021. PMID: 34352285. doi:10.1053/j.ajkd.2021.06.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。